Table 1.

Demographic and clinical characteristics of patients with recurrent angioedema (RAE) (n = 86) as well as their response to treatment and quality of life impairment as assessed by use of the Thai Angioedema Quality of Life questionnaire (AE-QoL), the Thai Dermatology Life Quality Index (DLQI), the Patient Global Assessment of Quality of Life (PGA-QoL)

				Values
Gender, n (%)
Female				69 (80.2%)
Male				17 (19.8%)
Diagnosis, n (%)
RAE without wheals				10 (11.6%)
RAE with wheals				76 (88.0%)
Range of scores (total score)
Thai AE-QoL				0–79.4 (100)
Thai DLQI				0–23 (30)
PGA-QoL				0–3 (4)
Disease severity of urticaria of 76 RAE patients with wheals
Urticaria activity score over 7 days (UAS7), n (%)
Urticaria-free (UAS7 = 0)				18 (23.7%)
Well-controlled CSU (UAS7 = 1–6)				13 (17.1%)
Mild activity CSU (UAS7 = 7–15)				26 (34.2%)
Moderate activity CSU (UAS7 16–27)				14 (18.4%)
Severe activity CSU (UAS7 = 28–42)				5 (6.6%)
Treatment, n (%)
H1-antihistamines				74 (86.0%)
H1-antihistamines + prednisolone				8 (9.3%)
H1-antihistamines + omalizumab				4 (4.7%)
Impairment of health-related quality of life using:
- PGA-QoL questionnaire, n (%)	AE-QoL total value mean ± SD (median)	1st quartile	3rd quartile
None	11.2 ± 14.2 (5.9)	0	19.1	35 (40.7%)
Mild	29.9 ± 13.2 (32.4)	20.6	38.2	31 (36.0%)
Moderate	49.3 ± 17.6 (52.2)	34.9	67.3	12 (14.0%)
Severe	46.9 ± 20.4 (42.6)	34.6	61.8	8 (9.3%)
Very severe	0	0	0	0 (0.0%)
- DLQI questionnaire, n (%)
No effect	11.6 ± 13.6 (5.9)	0	19.9	33 (38.4%)
Small effect	26.0 ± 15.3 (24.3)	16.9	34.6	22 (25.6%)
Moderate effect	39.7 ± 17.3 (38.2)	33.1	49.3	13 (15.1%)
Very large effect	42.2 ± 19 (42.6)	35.7	61.8	18 (20.9%)
Extremely large effect	0	0	0	0 (0.0%)